2017 Fiscal Year Final Research Report
Elucidation of the pathology of Guillain-Barre syndrome as rafts's disease
| Project/Area Number |
15K19500
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Fujita Health University |
|---|
Principal Investigator |
Ueda Akihiro 藤田保健衛生大学, 医学部, 准教授 (20600703)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | Guillain-Barre syndrome / anti-GM1 antibody / neutral sphingomyelinase / sphingomyelin / lipid rafts |
|---|
| Outline of Final Research Achievements |
Previous studies have shown that patients with Guillain-Barre syndrome express autoantibodies against GM1, although its pathogenic significance for the development of the disease remains to be elucidated.
nSMase2 is the best characterized neutral sphingomyelinase (nSMase) found in neuronal cells. We have explored the effects of anti-GM1 antibodies on sphingomyelin metabolism of PC12 cells stably transfected with human trk cDNA (PCtrk cells) by determining their effects on nSMase2 activity. The data we present here strongly suggest that anti-GM1 caused a significant change in ceramide and sphingomyelin content of the membrane fraction in PCtrk cells. Both nSMase2 activity and the level of nSMase2 protein were significantly decreased by anti-GM1 treatment of PCtrk cells, while acidic SMase activities remained unchanged. Our results indicate, for the first time, that anti-GM1 may produce profound impacts on lipid metabolism in neuronal cell membranes.
|
| Free Research Field |
神経内科学
|
